We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Creative Peptides has established an advanced surface plasmon resonance (SPR) platform with several applications for drug discovery, including fragment-based screening, targets characterization, lead optimization, and many other services that customer requires. This technique enables real time study of the interaction between immobilized receptors and analytes in solution without labelling of the analyte.
SPR is an extraordinary sensitive method for the detection of molecular interactions without lablelling. In general, binding response includes three phases: association, equilibrium and dissociation. Based on these data, scientist will use the mathematic model to calculate the association (Ka) and dissociation (Kd) rate constants and ultimately determine the binding affinity (KD). Different from isothermal calorimetry (ITC) that measures antibody binding affinity based on equilibrium point, SPR is able to obtain full kinetic parameters to evaluate all the effects of association and dissociation as well as antibody affinity.
In other hand, using a SPR biosentor to investigate blocking offers several advantages over enzyme-linked immunosorbent assay (ELISA), which requires labels and provides only an end-point analysis. Indeed, epitope binding via ELISA is often hindered by the inability of finding a secondary reagent that can detect one mAb selectively over another when mAbs are competed against one another in pairs. Although biotinylating or reformatting a mAb may distinguish it from other mAbs in a test panel, it can make sample preparation tedious and unsuitable for performing high-throughput screening in a combinatorial-type format. Furthermore, ELISA may be unfeasible if the plated reagent is precious and/or expensive. In contrast, SPR biosentor reveals the entire binding profile between an interacting pair of molecules without labels, and the ligand-coated surfaces and/or solution binding partners are able to be reused.
Antigen-Antibody interaction by SPR to test the possibility of several different monoclonal antibodies binding simultaneously to an antigen. A MAb is immobilized in a matrix and then the antigen and a sequence of MAbs are injected in turn. A complete epitope map is obtained by changing the sequence of antibodies until all combinations have been tested.
Antigen-Antibody interactions by SPR also provide a high-throughput way to test the possibility of monoclonal antibodies binding to an antigen. The analyzed antibodies are first been captured by high-affinity anti-IgG antibody immobilized on the sensor chip surface. Then a series of concentrations of antigens are sequentially injected across the surface. Based on the sensorgram curve, people can rank the antibodies according to the kinetic parameters and select monoclonal antibodies with the best characters of your preference.
Creative Peptides has extensive experience in providing One-stop-shop SPR services from synthesis of peptide antigen to SPR service. For more detailed information, please feel free to contact us at Email or directly sent us an inquiry.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com